OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with broad preventative and therapeutic applications, is pleased to announce that all the pending claims of a second patent application on the papillomavirus pseudovirus technology have been allowed by the U.S. Patent and Trademark Office. Bio-Bridge expects the second patent will be issued upon payment of the issue fee. The first U.S. patent (number 6,878,541 B2) on the papillomavirus pseudovirus technology was issued in 2005. The second patent covers broader aspects of the invention and further protects the intellectual property in the papillomavirus pseudovirus technology. Loyola University Chicago owns the patent and has exclusively licensed the technology to Bio-Bridge Science, Inc.
